

Ismael Buno

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9542131/publications.pdf>

Version: 2024-02-01

133
papers

1,982
citations

361413

20
h-index

276875

41
g-index

138
all docs

138
docs citations

138
times ranked

3173
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk prediction of CMV reactivation after allogeneic stem cell transplantation using five non-HLA immunogenetic polymorphisms. <i>Annals of Hematology</i> , 2022, 101, 1567-1576.	1.8	3
2	Post-transplant cyclophosphamide for GVHD prophylaxis compared to ATG-based prophylaxis in unrelated donor transplantation. <i>Annals of Hematology</i> , 2021, 100, 541-553.	1.8	25
3	Elafin as a Predictive Biomarker of Acute Skin Graft-Versus-Host Disease After Haploidentical Stem Cell Transplantation Using Post-Transplant High-Dose Cyclophosphamide. <i>Frontiers in Immunology</i> , 2021, 12, 516078.	4.8	9
4	Novel biallelic variant in BBS9 causative of Bardet-Biedl syndrome: expanding the spectrum of disease-causing genetic alterations. <i>BMC Medical Genomics</i> , 2021, 14, 91.	1.5	2
5	Clinical Utility of the Detection of the Loss of the Mismatched HLA in Relapsed Hematological Patients After Haploidentical Stem Cell Transplantation With High-Dose Cyclophosphamide. <i>Frontiers in Immunology</i> , 2021, 12, 642087.	4.8	9
6	Next Generation Cytogenetics in Myeloid Hematological Neoplasms: Detection of CNVs and Translocations. <i>Cancers</i> , 2021, 13, 3001.	3.7	2
7	Clinical utility of targeted next-generation sequencing for the diagnosis of myeloid neoplasms with germline predisposition. <i>Molecular Oncology</i> , 2021, 15, 2273-2284.	4.6	5
8	Incorporating genetic and clinical data into the prediction of thromboembolism risk in patients with lymphoma. <i>Cancer Medicine</i> , 2021, 10, 7585-7592.	2.8	7
9	Genetic biomarkers identify a subgroup of high-risk patients within low-risk NPM1-mutated acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 1178-1186.	1.3	1
10	Cell-Free DNA Dynamic Concentration, CRP and LDH Pre-Infusion Are Predictors of Early Progression after CAR T-Cell Therapy in DLBCL Patients. <i>Blood</i> , 2021, 138, 1761-1761.	1.4	0
11	Exome sequencing reveals heterogeneous clonal dynamics in donor cell myeloid neoplasms after stem cell transplantation. <i>Haematologica</i> , 2020, 105, 2655-2658.	3.5	1
12	Short Tandem Repeats (STRs) as Biomarkers for the Quantitative Follow-Up of Chimerism after Stem Cell Transplantation: Methodological Considerations and Clinical Application. <i>Genes</i> , 2020, 11, 993.	2.4	19
13	Variable selection with P-splines in functional linear regression: Application in graft-versus-host disease. <i>Biometrical Journal</i> , 2020, 62, 1670-1686.	1.0	2
14	Meta-Analysis of Genome-Wide Association and Gene Expression Studies Implicates Donor T Cell Function and Cytokine Pathways in Acute GvHD. <i>Frontiers in Immunology</i> , 2020, 11, 19.	4.8	6
15	Impact of Minimal Residual Disease and Chimerism Monitoring at Different Timepoints after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 7-7.	1.4	1
16	Association of Gene Polymorphisms in Cyclophosphamide Metabolism Pathway with Complications after Haploidentical Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 14-15.	1.4	0
17	ST2 and REG3 β as Predictive Biomarkers After Haploidentical Stem Cell Transplantation Using Post-transplantation High-Dose Cyclophosphamide. <i>Frontiers in Immunology</i> , 2019, 10, 2338.	4.8	16
18	Successful Treatment of Severe Aspergillosis with Isavuconazole Therapy after Allogeneic Stem Cell Transplantation. <i>Chemotherapy</i> , 2019, 64, 57-61.	1.6	2

#	ARTICLE	IF	CITATIONS
19	Next-Generation Sequencing Improves Diagnosis, Prognosis and Clinical Management of Myeloid Neoplasms. <i>Cancers</i> , 2019, 11, 1364.	3.7	23
20	Posttransplant cyclophosphamide vs cyclosporin A and methotrexate as GVHD prophylaxis in matched sibling transplantation. <i>Blood Advances</i> , 2019, 3, 3351-3359.	5.2	25
21	Allogeneic stem-cell transplantation in HIV-1-infected patients with high-risk hematological disorders. <i>Aids</i> , 2019, 33, 1441-1447.	2.2	13
22	Post-Transplant Cyclophosphamide for Gvhd Prophylaxis in Matched Unrelated Donor Transplantation Compared to ATG-Based Prophylaxis. <i>Blood</i> , 2019, 134, 3285-3285.	1.4	1
23	Familial low phospholipid-associated cholelithiasis resulting from an autosomal dominant ABCB4 mutation. <i>Revista Espanola De Enfermedades Digestivas</i> , 2019, 111, 806-808.	0.3	1
24	S1640 POLYMORPHISMS IN CYTOKINES, CHEMOKINES AND THEIR RECEPTORS GENES CONTRIBUTED TO CYTOMEGALOVIRUS REACTIVATION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION. <i>HemaSphere</i> , 2019, 3, 758-759.	2.7	0
25	Liquid Biopsy Is Useful to Identify the Genetic Profile of NHL-B at Diagnosis in Different Histological Subtypes. <i>Blood</i> , 2019, 134, 5216-5216.	1.4	0
26	Identification of New Polymorphisms in Genes of the Immune System Associated with Acute Graft Versus Host Disease after Identical HLA-Allogeneic Stem-Cell Transplantation. <i>Blood</i> , 2019, 134, 3286-3286.	1.4	0
27	Whole-exome sequencing reveals acquisition of mutations leading to the onset of donor cell leukemia after hematopoietic transplantation: a model of leukemogenesis. <i>Leukemia</i> , 2018, 32, 1822-1826.	7.2	10
28	Donor Cell-Derived Hematologic Neoplasms after Hematopoietic Stem Cell Transplantation: A Systematic Review. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1505-1513.	2.0	22
29	Wilms Tumor 1 gene expression levels improve risk stratification in <sc>AML</sc> patients. Results of a multicentre study within the Spanish Group for Molecular Biology in Haematology. <i>British Journal of Haematology</i> , 2018, 181, 542-546.	2.5	4
30	Mechanisms That Contribute to a Profound Reduction of the HIV-1 Reservoir After Allogeneic Stem Cell Transplant. <i>Annals of Internal Medicine</i> , 2018, 169, 674.	3.9	59
31	A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms. <i>Blood Advances</i> , 2018, 2, 1719-1737.	5.2	25
32	Busulfan-based myeloablative conditioning regimens for haploidentical transplantation in high-risk acute leukemias and myelodysplastic syndromes. <i>European Journal of Haematology</i> , 2018, 101, 332-339.	2.2	11
33	PD-1 genotype of the donor is associated with acute graft-versus-host disease after HLA-identical sibling donor stem cell transplantation. <i>Annals of Hematology</i> , 2018, 97, 2217-2224.	1.8	8
34	Post-Transplant Cyclophosphamide Versus MTX-CSA As Gvhd Prophylaxis in HLA-Identical Sibling HSCT. <i>Blood</i> , 2018, 132, 3394-3394.	1.4	0
35	Serial Lineage Chimerism Analysis Improves Early Diagnosis of Graft Failure after Allogeneic HSCT. <i>Blood</i> , 2018, 132, 5704-5704.	1.4	0
36	Leukemogenesis in Seven Donor Cell Derived Myeloid Neoplasms Patients. Whole Exome Sequencing Reveals Clonal Dynamics. <i>Blood</i> , 2018, 132, 2752-2752.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Monosomal karyotype in chronic lymphocytic leukemia: Association with clinical and biological features and potential prognostic significance. <i>American Journal of Hematology</i> , 2017, 92, E132-E135.	4.1	1
38	Haplo-Cord transplantation compared to haploidentical transplantation with post-transplant cyclophosphamide in patients with AML. <i>Bone Marrow Transplantation</i> , 2017, 52, 1138-1143.	2.4	20
39	Transient hemolysis due to anti-CD and anti-CA 1 produced by engrafted donor's lymphocytes after allogeneic unmanipulated haploidentical hematopoietic stem cell transplantation. <i>Transfusion</i> , 2017, 57, 2355-2358.	1.6	3
40	SF3B1 Mutation in Low-Risk MDS: Impact of its Incorporation to the Updated 2016 Who Classification and Relationship with Ferric Overload. <i>Leukemia Research</i> , 2017, 55, S111-S112.	0.8	0
41	Donor CTLA-4 Genotype Modulates the Immune Response to Minor Histocompatibility Antigen Mismatches. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2042-2047.	2.0	13
42	Single umbilical cord blood with or without CD34+ cells from a third-party donor in adults with leukemia. <i>Blood Advances</i> , 2017, 1, 1047-1055.	5.2	6
43	PTCH1 is a reliable marker for predicting imatinib response in chronic myeloid leukemia patients in chronic phase. <i>PLoS ONE</i> , 2017, 12, e0181366.	2.5	8
44	Inhibitory killer cell immunoglobulin-like receptor (KIR) mismatches improve survival after T-cell repleted haploidentical transplantation. <i>European Journal of Haematology</i> , 2016, 96, 483-491.	2.2	15
45	Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: Spanish multicenter experience. <i>Bone Marrow Transplantation</i> , 2016, 51, 1307-1312.	2.4	31
46	In vivo adhesion of malignant B cells to bone marrow microvasculature is regulated by β 2 integrin cytoplasmic-binding proteins. <i>Leukemia</i> , 2016, 30, 861-872.	7.2	26
47	Indole-3-Carbinol Synergizes with and Restores Fludarabine Sensitivity in Chronic Lymphocytic Leukemia Cells Irrespective of p53 Activity and Treatment Resistances. <i>Clinical Cancer Research</i> , 2016, 22, 134-145.	7.0	8
48	UGT2B17 minor histocompatibility mismatch and clinical outcome after HLA-identical sibling donor stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2016, 51, 79-82.	2.4	14
49	Whole Exome Sequencing Reveals Acquisition of Mutations Leading to the Onset of Donor Cell Leukemia after Hematopoietic Transplantation. a Model of Leukemogenesis. <i>Blood</i> , 2016, 128, 2879-2879.	1.4	0
50	Antithymocyte Globulin-Based Prophylaxis for Graft Versus Host Disease Compared to Post-Transplant Cyclophosphamide-Based Prophylaxis in Matched Unrelated Donor Transplantation. <i>Blood</i> , 2016, 128, 2307-2307.	1.4	12
51	Evaluation of Donor KIR2DL1 Allelic Polymorphism in the Setting of T-Cell Repleted Haploidentical Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S327.	2.0	0
52	CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia. <i>Haematologica</i> , 2015, 100, e183-e185.	3.5	20
53	The Genotype of the Donor for the (GT) _n Polymorphism in the Promoter/Enhancer of FOXP3 Is Associated with the Development of Severe Acute GVHD but Does Not Affect the CVL Effect after Myeloablative HLA-Identical Allogeneic Stem Cell Transplantation. <i>PLoS ONE</i> , 2015, 10, e0140454.	2.5	11
54	Correlation of myelodysplastic syndromes with i(17)(q10) and TP53 and SETBP1 mutations. <i>British Journal of Haematology</i> , 2015, 171, 137-141.	2.5	11

#	ARTICLE	IF	CITATIONS
55	Haploidentical Stem Cell Transplantation (HAPLO-HSCT) with Busulfan (BUX) Based Reduced Intensity Conditioning (RIC) Regimens and Post-Transplant Cyclophosphamide (PT-CY) as GVHD Prophylaxis in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL). <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S85-S86.	2.0	2
56	Effect of mismatching for mHA UTA2-1 on clinical outcome after HLA-identical sibling donor allo-SCT. <i>Bone Marrow Transplantation</i> , 2015, 50, 298-300.	2.4	1
57	Fluorescence <i>in situ</i> hybridization of TP53 for the detection of chromosome 17 abnormalities in myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2015, 56, 3183-3188.	1.3	2
58	Achievement of early complete donor chimerism in CD25+ activated leukocytes is a strong predictor of the development of graft-versus-host-disease after stem cell transplantation. <i>Experimental Hematology</i> , 2015, 43, 4-13.e1.	0.4	4
59	Measurement of PTCH1 Expression at Diagnosis Is an Appropriate Tool for Tyrosine Kinase Inhibitors Selection in Chronic Myeloid Leukemia Patients in Chronic Phase. <i>Blood</i> , 2015, 126, 2791-2791.	1.4	0
60	A New Multiple Single-Nucleotide Polymorphisms Based Predictive Model for Grades III to IV and Extensive Graft Versus Host Disease after Identical HLA-Allogeneic Stem-Cell. <i>Blood</i> , 2015, 126, 921-921.	1.4	4
61	A Novel Quantitative PCR Approach Targeting Insertion/Deletion Polymorphisms (Indel-PCR) for Chimerism Quantification: Finally High Sensitivity and Quantification Capacity Together. <i>Blood</i> , 2015, 126, 4277-4277.	1.4	0
62	39 Phytochemical indole-3-carbinol synergizes strongly with fludarabine and induces p53-dependent and -independent cell death in chronic lymphocytic leukemia cells irrespective of their IGHV mutation state and treatment resistances. <i>European Journal of Cancer</i> , 2014, 50, 18.	2.8	1
63	Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation. <i>European Journal of Haematology</i> , 2014, 93, 239-246.	2.2	60
64	Hypermethylation of the alternative AWT1 promoter in hematological malignancies is a highly specific marker for acute myeloid leukemias despite high expression levels. <i>Journal of Hematology and Oncology</i> , 2014, 7, 4.	17.0	21
65	Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm. <i>Leukemia</i> , 2014, 28, 823-829.	7.2	148
66	Early peripheral blood and T-cell chimerism dynamics after umbilical cord blood transplantation supported with haploidentical cells. <i>Bone Marrow Transplantation</i> , 2014, 49, 212-218.	2.4	17
67	Haplo-Cord Transplantation Using CD34+ Cells from a Third-Party Donor to Speed Engraftment in High-Risk Patients with Hematologic Disorders. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 2015-2022.	2.0	42
68	Immunoglobulin and T Cell Receptor Gene High-Throughput Sequencing Quantifies Minimal Residual Disease in Acute Lymphoblastic Leukemia and Predicts Post-Transplantation Relapse and Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1307-1313.	2.0	124
69	Donor and Recipient Genotypes for Interleukin 1 Gene Single Nucleotide Polymorphisms (SNPs) Allow Anticipation of Acute Graft Versus Host Disease after HLA-Identical Allogeneic Stem Cell Transplantation (allo-SCT). <i>Blood</i> , 2014, 124, 666-666.	1.4	1
70	Graft Versus HIV-1 Reservoir Effect after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 1234-1234.	1.4	0
71	Differences in Natural Killer(NK) Reconstitution Between Unmanipulated Haploidentical and HLA Identical Stem Cell Transplantation and Relationship with Citomegalovirus and Graft Versus Host Disease (GVHD). Experience in One Centre in 22 Patients.. <i>Blood</i> , 2014, 124, 5872-5872.	1.4	0
72	Myelodysplastic Syndromes with I(17)(q10) and Prognostic Implications of Mutations of TP53 and SETBP1. <i>Blood</i> , 2014, 124, 1910-1910.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Wilmsâ€™ Tumor 1 Expression Levels in Bone Marrow after Induction and/or Consolidation Therapy Allow a Better Stratification of Patients and Improves Treatment in Adult AML. <i>Blood</i> , 2014, 124, 1036-1036.	1.4	0
74	Graft-Versus-Tumor Effect After Allogeneic Stem Cell Transplantation in HIV-Positive Patients With High-Risk Hematologic Malignancies. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1340-1345.	1.1	16
75	Mutation of the NPM1 gene contributes to the development of donor cellâ€™derived acute myeloid leukemia after unrelated cord blood transplantation for acute lymphoblastic leukemia. <i>Human Pathology</i> , 2013, 44, 1696-1699.	2.0	12
76	Application of FISH 7q in MDS patients without monosomy 7 or 7q deletion by conventional G-banding cytogenetics: Does â€™7/7qâ€™ detection by FISH have prognostic value?. <i>Leukemia Research</i> , 2013, 37, 416-421.	0.8	16
77	Single Cord Blood Combined with HLA-Mismatched Third Party Donor Cells: Comparable Results to Matched Unrelated Donor Transplantation in High-Risk Patients with Hematologic Disorders. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 143-149.	2.0	28
78	A variant in IRF3 impacts on the clinical outcome of AML patients submitted to Allo-SCT. <i>Bone Marrow Transplantation</i> , 2013, 48, 1205-1211.	2.4	7
79	A polymorphism in the <i>TYMP</i> gene is associated with the outcome of HLAâ€™identical sibling allogeneic stem cell transplantation. <i>American Journal of Hematology</i> , 2013, 88, 883-889.	4.1	7
80	Haploidentical Stem Cell Transplantation (HAPLO-HSCT) With Reduced Intensity Conditioning (RIC) Regimens and High Dose Cyclophosphamide Post-Transplant (HD-CY) As Gvhd Prophylaxis In Patients With Relapsed Or Refractory Hodgkinâ€™s Disease: Multicentric Spanish Experience. <i>Blood</i> , 2013, 122, 3406-3406.	1.4	4
81	Early and Favourable Immune Reconstitution After Unmanipulated Haploidentical Stem Cell Transplantation With High Dose Post-Transplant Cyclophosphamide Regardless Intensity Of Conditioning Regimen. <i>Blood</i> , 2013, 122, 4620-4620.	1.4	2
82	Chronic Myeloid Leukemia (CML) Patients With Atypical e1a2 P190 BCR-ABL Translocation Show a Poor Response To Therapy With Tyrosine Kinase Inhibitors (TKI). <i>Blood</i> , 2013, 122, 5193-5193.	1.4	4
83	Single Cord Blood Transplantation Combined With An HLA Mismatched Third Party Donor For High-Risk Hematological Patients With HIV Infection. <i>Blood</i> , 2013, 122, 3401-3401.	1.4	2
84	Early Evaluation Of Natural Killer Cell Reconstitution Following Unmanipulated Haploidentical Transplantation Compared With HLA-Identical Sibling Transplantation. <i>Blood</i> , 2013, 122, 5480-5480.	1.4	0
85	Haploidentical Stem Cell Transplantation (HAPLO-HSCT) With High Dose Cyclophosphamide Post-Transplant (HD-CY) As Gvhd Prophylaxis In High Risk Hematologic Malignancies: Multicentric Spanish Experience. <i>Blood</i> , 2013, 122, 2173-2173.	1.4	0
86	The Presence Of Residual Disease After Induction and/Or Consolidation Therapy Based On Wilmsâ€™ Tumor 1 (WT1) Expression Is a Strong Prognostic Factor For Relapse and Survival In AML. <i>Blood</i> , 2013, 122, 1329-1329.	1.4	0
87	Donor Genotypes For Interleukin-17A Gene Single Nucleotide Polymorphisms (SNPs) Allow Anticipation Of Complications After HLA-Identical Allogeneic Stem Cell Transplantation (allo-SCT). <i>Blood</i> , 2013, 122, 4619-4619.	1.4	0
88	Mismatches In Killer Immunoglobulin Receptor (KIR) Ligands and Inhibitory KIR Receptors Between Donor and Recipients Improve Survival After Non T Cell Depleted Haploidentical Transplantation. <i>Blood</i> , 2013, 122, 2009-2009.	1.4	0
89	Donor CTLA-4 Genotype Influences Clinical Outcome after T Cell-Depleted Allogeneic Hematopoietic Stem Cell Transplantation from HLA-Identical Sibling Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 100-105.	2.0	18
90	Iv Busulfan Based Conditioning Regimen for Haploidentical Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, S354.	2.0	1

#	ARTICLE	IF	CITATIONS
91	Evaluation of Minimal Residual Disease by Real-Time Quantitative PCR of Wilms's Tumor 1 Expression in Patients with Acute Myelogenous Leukemia after Allogeneic Stem Cell Transplantation: Correlation with Flow Cytometry and Chimerism. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1235-1242.	2.0	57
92	Fragment length analysis screening for detection of CEBPA mutations in intermediate-risk karyotype acute myeloid leukemia. <i>Annals of Hematology</i> , 2012, 91, 1-7.	1.8	13
93	Minimal Residual Disease Quantification in Acute Lymphoblastic Leukemia Using High-Throughput Sequencing of Multiple Immunoreceptor Genes Predicts Relapse and Survival After Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2012, 120, 2512-2512.	1.4	2
94	A Gene Variant in IRF3 Impacts On the Clinical Outcome of Acute Myeloid Leukemia (AML) Patients Submitted to Allogeneic Stem Cell Transplantation (allo-SCT). <i>Blood</i> , 2012, 120, 468-468.	1.4	4
95	Value of Pretransplantation Minimal Residual Disease in Acute Myeloid Leukemia and Myeloablative Hematopoietic Cell Transplantation. <i>Blood</i> , 2012, 120, 2510-2510.	1.4	0
96	Haploidentical Transplantation (HAPLO) with Post-Transplant High-Dose Cyclophosphamide for Graft Vs Host Disease (GVHD) Prevention in the Treatment of High Risk Hematological Neoplasms. <i>Blood</i> , 2012, 120, 4545-4545.	1.4	0
97	Usefulness of the Quantitative Follow-up of Chimerism in Cell-Free Plasma DNA for the Prediction/Early Diagnosis of Complications After Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 4146-4146.	1.4	0
98	Immune Reconstitution After Autologous Stem Cell Transplantation: Is There Any Difference Between HIV+ and HIV- Patients?. <i>Blood</i> , 2012, 120, 4665-4665.	1.4	0
99	High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 21194-21199.	7.1	160
100	Dynamics of Chimerism In Regulatory T Lymphocytes (Treg; CD4+/CD25+) After Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2010, 116, 1328-1328.	1.4	0
101	High-Throughput VDJ Sequencing Is Superior to Quantitative PCR and Flow Cytometry for the Quantification of Minimal Residual Disease In Chronic Lymphocytic Leukemia After Hematopoietic Cell Transplantation. <i>Blood</i> , 2010, 116, 1290-1290.	1.4	0
102	Essential thrombocythemia in patients with platelet counts below $600 \times 10^9/L$: Applicability of the 2008 World Health Organization diagnostic criteria revision proposal. <i>American Journal of Hematology</i> , 2009, 84, 452-454.	4.1	2
103	Mesenteric inflammatory veno-occlusive disease (MIVOD) after allogeneic peripheral blood stem cell transplantation (PBSCT). <i>Bone Marrow Transplantation</i> , 2008, 41, 311-313.	2.4	5
104	475: Why are some Stem Cell Transplant Candidates (SCT) not Finally Transplanted? the Experience of a SCT Team using an Electronic Tool to Manage the Transplant Schedule. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 167-168.	2.0	0
105	Clinical usefulness of the electronic management of the stem cell transplant schedule: Clinical evolution of candidate patients. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 172.	2.0	0
106	Post-Transplant Lymphoproliferative Disorder Mimicking a Thrombotic Microangiopathy. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 1203-1205.	2.0	2
107	Heterogeneous loss of the Y chromosome in leukocyte lineages of donor origin after stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2006, 38, 463-465.	2.4	1
108	Listeria monocytogenes meningitis in two allogeneic hematopoietic stem cell transplant recipients. <i>Leukemia and Lymphoma</i> , 2006, 47, 1701-1703.	1.3	10

#	ARTICLE	IF	CITATIONS
109	Reliable quantification of hematopoietic chimerism after allogeneic transplantation for acute leukemia using amplification by real-time PCR of null alleles and insertion/deletion polymorphisms. <i>Leukemia</i> , 2005, 19, 336-343.	7.2	68
110	HIV-associated lymphoma successfully treated with peripheral blood stem cell transplantation. <i>Experimental Hematology</i> , 2005, 33, 487-494.	0.4	83
111	Lymphoma associated chromosomal abnormalities can easily be detected by FISH on tissue imprints. An underused diagnostic alternative. <i>Journal of Clinical Pathology</i> , 2005, 58, 629-633.	2.0	15
112	A comparison of fluorescent in situ hybridization and multiplex short tandem repeat polymerase chain reaction for quantifying chimerism after stem cell transplantation. <i>Haematologica</i> , 2005, 90, 1373-9.	3.5	43
113	Successful treatment of incipient graft rejection with donor leukocyte infusions, further proof of a graft versus host lymphohaemopoietic effect. <i>Bone Marrow Transplantation</i> , 2004, 33, 1037-1041.	2.4	10
114	Mosaicism for Sister Chromatid Heterogeneity in Sex Chromosomes from Hybrids of two Subspecies of <i>Chorthippus Parallelus</i> (Orthoptera: Acrididae). <i>Hereditas</i> , 2004, 122, 289-292.	1.4	1
115	Sex is Determined by Sex Chromosomes in <i>Littorina Saxatilis</i> (Olivi) (Gastropoda, Prosobranchia). <i>Hereditas</i> , 2004, 124, 261-268.	1.4	13
116	Quantification of donor and recipient hemopoietic cells by real-time PCR of single nucleotide polymorphisms. <i>Leukemia</i> , 2003, 17, 621-629.	7.2	80
117	Quantification of donor and recipient hemopoietic cells by real-time PCR of single nucleotide polymorphisms. <i>Leukemia</i> , 2003, 17, 630-633.	7.2	21
118	Lineage-specific Chimaerism Quantification after T-cell Depleted Peripheral Blood Stem Cell Transplantation. <i>Leukemia and Lymphoma</i> , 2003, 44, 659-667.	1.3	11
119	Sequential fluorescence in situ hybridization for the quantification of minimal residual disease in recipient cells after sex-mismatched allogeneic stem cell transplantation. <i>British Journal of Haematology</i> , 2002, 118, 349-349.	2.5	1
120	<i>Sau</i> 3A in situ digestion of human chromosome 3 pericentromeric heterochromatin. I. Differential digestion of α -satellite and satellite 1 DNA sequences. <i>Genome</i> , 2001, 44, 120-127.	2.0	2
121	Diagnostic utility of fluorescence in situ hybridization in mantle-cell lymphoma. <i>British Journal of Haematology</i> , 2000, 110, 856-862.	2.5	109
122	Chimerism Quantification after Sex-Matched BMT. <i>Cancer Genetics and Cytogenetics</i> , 1999, 113, 152-155.	1.0	0
123	Image Processing and Analysis of Fluorescent Labelled Cytoskeleton. <i>Micron</i> , 1998, 29, 445-449.	2.2	12
124	Elevated Levels of Interferon Gamma, Tumor Necrosis Factor α , Interleukins 2, 4, and 5, but Not Interleukin 10, Are Present in Recurrent Aphthous Stomatitis. <i>Archives of Dermatology</i> , 1998, 134, 827-31.	1.4	114
125	The Enamel Paint Sign in the Dermatologic Diagnosis of Early-Onset Kwashiorkor. <i>Archives of Dermatology</i> , 1998, 134, 107-108.	1.4	20
126	Dynamics of <i>Sau</i> 3A in situ digestion of human chromosomes analyzed with computerized imaging. <i>Genome</i> , 1997, 40, 123-126.	2.0	3

#	ARTICLE	IF	CITATIONS
127	<i>Alu</i> in situ digestion of human aliphoid and classical satellite DNA regions: High-resolution digital image analysis of FISH signals from condensed and extended chromatin. <i>Cytogenetic and Genome Research</i> , 1997, 76, 94-100.	1.1	11
128	Quantification of C-ERB-B2 gene amplification in breast cancer cells using fluorescence in situ hybridization and digital image analysis. <i>Cancer Genetics and Cytogenetics</i> , 1996, 86, 18-21.	1.0	21
129	Restriction endonuclease in situ digestion (REISD) and fluorescence in situ hybridization (FISH) as complementary methods to analyze chimerism and residual disease after bone marrow transplantation. <i>Cancer Genetics and Cytogenetics</i> , 1996, 89, 141-145.	1.0	3
130	DIGITAL IMAGE ANALYSIS OF CHROMATIN FIBRE PHENOTYPE AFTER 'IN SITU' DIGESTION WITH RESTRICTION ENDONUCLEASES. <i>Cell Biology International</i> , 1996, 20, 213-217.	3.0	1
131	Digital image analysis of chromatin fibre phenotype after "in situ" digestion with restriction endonucleases. <i>Cell Biology International</i> , 1995, 19, 827-832.	3.0	2
132	A hybrid zone between two subspecies of the grasshopper <i>Chorthippus parallelus</i> along the Pyrenees: the west end. <i>Heredity</i> , 1994, 73, 625-634.	2.6	19
133	Sister chromatid differentiation after in situ detection of ultraviolet-induced DNA breaks under electron microscopy. <i>Biology of the Cell</i> , 1994, 82, 33-37.	2.0	0